Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778425 | 0.93 | TLR7 (0.43) | TLR7TLR8NUDT1 | |
| SCHEMBL6778072 | 0.90 | TLR7 (0.41) | TLR7TLR8NUDT1 | |
| SCHEMBL6783890 | 0.90 | TLR7 (0.41) | TLR7TLR8NUDT1 | |
| SCHEMBL6283865 | 0.90 | TLR7 (0.41) | TLR7TLR8NUDT1 | |
| SCHEMBL6774751 | 0.88 | TLR7 (0.43) | TLR7TLR8NUDT1 | |
| SCHEMBL4793789 | 0.88 | TLR8 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL6778433 | 0.87 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL4792114 | 0.87 | TLR8 (0.40) | TLR7TLR8NUDT1 | |
| SCHEMBL4795563 | 0.87 | TLR8 (0.41) | TLR7TLR8NUDT1 | |
| SCHEMBL6774225 | 0.86 | KMT2A (0.40) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453829-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | claimed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | claimed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | claimed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1453829-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-6696465-B2 | INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-24 | — | — | US | disclosed |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | IRF3, EIF2AK2, MYD88 | TLR7 52/4885TLR8 62/4885NUDT1 860/4885 |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | IRF3, EIF2AK2, MYD88 | TLR7 52/4885TLR8 62/4885NUDT1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.